Medicenna Therapeutics Corp. is set to report its earnings on June 24, 2026, with expectations of a loss per share of CA$0.06. Investors will be keen to see how the clinical-stage company is progressing after its recent fundraising efforts.
Scheduled for release after market close on June 24, 2026, Medicenna will unveil its earnings for the fiscal period ending March 31, 2026. Analysts anticipate the company will report an EPS of -CA$0.06. However, since there’s no actual figure yet available, the focus will be on updates regarding its clinical programs and financial health following its recent public offering.
Investor takeaway: Long-term investors should monitor Medicenna's clinical advancements and financial stability as the company navigates its growth phase.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$43.38M
52W high
$1.97
52W low
$0.34
1W change
+2.17%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 580.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+580.9% Upside
Current Price
C$0.47
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
61.7%
Annualized
90-Day Vol
65.8%
Annualized
Trend (90d)
+47.2%
Annualized drift
90d Mean
C$0.56
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.50 | C$0.40 – C$0.62 |
| 60 trading days | C$0.53 | C$0.39 – C$0.71 |
| 90 trading days | C$0.56 | C$0.38 – C$0.80 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Earnings Expectations: What Investors Should Note
With an EPS estimate of -CA$0.06, Medicenna's upcoming earnings report will be crucial for investors looking to gauge the company's financial trajectory. The absence of an actual EPS figure raises questions about its operational performance and future outlook.
Bull case
- Medicenna recently raised CA$4.44 million through a public offering, which could strengthen its development programs.
- The appointment of Dr. Nageatte Ibrahim as Chief Medical Officer brings valuable expertise that may speed up the company’s pipeline advancements.
- The potential for its Superkines to address significant unmet medical needs in oncology could attract future investments and partnerships.
Bear case
- The company has a high forward P/E ratio of 232.56x, suggesting it may be overvalued compared to its current earnings.
- With a profit margin of 0.00%, Medicenna faces challenges in becoming profitable amid ongoing clinical trials.
- The lack of actual EPS data could create uncertainty and volatility in stock performance after the earnings report.
Recent Fundraising Efforts
Advertisement
Medicenna recently closed a public offering, raising about CA$4.44 million to support its lead programs. This influx of capital is expected to boost the company’s ability to advance its clinical trials and develop its Superkines, which target cancer and autoimmune diseases.
Leadership Changes and Strategic Direction
The appointment of Dr. Nageatte Ibrahim as Chief Medical Officer is a significant move for Medicenna. With her extensive background in oncology and drug development, she is expected to drive the clinical strategy forward, particularly for the company’s promising IL-2 Superkine programs.
Market Position and Future Outlook
Medicenna operates in a competitive landscape as a clinical-stage immunotherapy company. As it prepares to release its earnings, investors will be keenly interested in how the company plans to leverage its recent capital raise and leadership changes to enhance its market position and ultimately achieve profitability.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
